These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 28842137)

  • 1. Rituximab Improves the Outcome of Patients With Grade 3 Follicular Lymphoma Receiving Anthracycline-Based Therapy.
    Yuan J; Greiner TC; Fu K; Smith LM; Aoun P; Chan WC; Bierman PJ; Bociek RG; Vose JM; Armitage JO; Weisenburger DD
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):488-497.e2. PubMed ID: 28842137
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era.
    Mustafa Ali M; Rybicki L; Nomani L; Rouphail B; Dean RM; Hill BT; Jagadeesh D; Pohlman B; Hsi ED; Smith MR
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):797-803. PubMed ID: 28789937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival.
    Hans CP; Weisenburger DD; Vose JM; Hock LM; Lynch JC; Aoun P; Greiner TC; Chan WC; Bociek RG; Bierman PJ; Armitage JO
    Blood; 2003 Mar; 101(6):2363-7. PubMed ID: 12424193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience.
    Ganti AK; Weisenburger DD; Smith LM; Hans CP; Bociek RG; Bierman PJ; Vose JM; Armitage JO
    Ann Oncol; 2006 Jun; 17(6):920-7. PubMed ID: 16524969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy.
    Shustik J; Quinn M; Connors JM; Gascoyne RD; Skinnider B; Sehn LH
    Ann Oncol; 2011 May; 22(5):1164-1169. PubMed ID: 21062969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
    Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
    Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysis.
    Pouyiourou M; Meyer A; Stroux A; Viardot A; La Rosée P; Maschmeyer G; Kämpfe D; Kahl C; Vucinic V; Monecke A; Hirt C; Weber T; Meissner J; Witzens-Harig M; Böttcher S; Schmalenberg H; Marks R; Prange-Krex G; Kroschinsky F; Hauf E; Keller U; Koch K; Klapper W; Herold M; Scholz CW;
    Ann Hematol; 2020 Dec; 99(12):2821-2829. PubMed ID: 32734548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-grade Follicular Lymphomas Exhibit Clinicopathologic, Cytogenetic, and Molecular Diversity Extending Beyond Grades 3A and 3B.
    Laurent C; Adélaïde J; Guille A; Tesson B; Gat E; Evrard S; Escudié F; Syrykh C; Canioni D; Fabiani B; Meignin V; Chassagne-Clement C; Dartigues P; Traverse-Glehen A; Parrens M; Huet S; Copie-Bergman C; Salles G; Birnbaum D; Brousset P; Morschhauser F; Xerri L;
    Am J Surg Pathol; 2021 Oct; 45(10):1324-1336. PubMed ID: 34334687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
    Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.
    Mondello P; Steiner N; Willenbacher W; Cerchione C; Nappi D; Mauro E; Ferrero S; Cuzzocrea S; Mian M
    Oncologist; 2018 Apr; 23(4):454-460. PubMed ID: 29317554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and 2.
    Horn H; Kohler C; Witzig R; Kreuz M; Leich E; Klapper W; Hummel M; Loeffler M; Trümper L; Spang R; Rosenwald A; Ott G;
    Haematologica; 2018 Jul; 103(7):1182-1190. PubMed ID: 29567771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi.
    Rossi G; Marcheselli L; Dondi A; Bottelli C; Tucci A; Luminari S; Arcaini L; Merli M; Pulsoni A; Boccomini C; Puccini B; Micheletti M; Martinelli G; Rossi A; Zilioli VR; Bozzoli V; Balzarotti M; Bolis S; Cabras MG; Federico M
    Am J Hematol; 2015 Jan; 90(1):56-61. PubMed ID: 25327841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of surveillance computed tomography in the follow-up of diffuse large B-cell and follicular lymphomas.
    Lin TL; Kuo MC; Shih LY; Dunn P; Wang PN; Wu JH; Tang TC; Chang H; Hung YS; Lu SC
    Ann Hematol; 2012 Nov; 91(11):1741-5. PubMed ID: 22729139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunophenotypic features and t(14;18) (q32;q21) translocation of Chinese follicular lymphomas helps to distinguish subgroups.
    Zhang F; Yan LX; Lin SX; Ye ZY; Zhuang HG; Yun JP; Lin HL; Luo DL; Xu FP; Luo XL; Cheng J; Zhang KP; Liu YH
    Diagn Pathol; 2013 Sep; 8():154. PubMed ID: 24047469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of anthracyclines in combination chemotherapy for the treatment of follicular lymphoma: retrospective study of the Intergruppo Italiano Linfomi on 761 cases.
    Rigacci L; Federico M; Martelli M; Zinzani PL; Cavanna L; Bellesi G; Merli F; Alterini R; Petrucci MT; Tani M; Liberati AM; Vitolo U; Pavone V; Cuneo A; Chisesib T; Brugiatelli M;
    Leuk Lymphoma; 2003 Nov; 44(11):1911-7. PubMed ID: 14738142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy.
    Ayoub Z; Andraos T; Milgrom SA; Pinnix CC; Dabaja BS; Ng SP; Gunther JR; Khoury JD; Fowler NH; Neelapu SS; Samaniego F; Fayad LE; Nastoupil LJ
    Leuk Lymphoma; 2019 Oct; 60(10):2432-2440. PubMed ID: 30942648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of Treatment in Slovene Follicular Lymphoma Patients.
    Južnič Šetina T; Borštnar S; Jezeršek Novaković B
    Clin Lymphoma Myeloma Leuk; 2015 Oct; 15(10):586-91. PubMed ID: 26423702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab maintenance improves overall survival in follicular lymphoma: A retrospective nationwide real-world analysis from Taiwan Cancer Registry Database.
    Huang HH; Wen YC; Chen HM; Hsiao FY; Ko BS
    Cancer Med; 2018 Aug; 7(8):3582-3591. PubMed ID: 30009424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up.
    Bari A; Marcheselli R; Marcheselli L; Alvarez I; Pozzi S; Ferri P; Lazzaro A; Fragasso A; Neri S; Baldini L; Carella AM; Angrilli F; Guariglia R; Buda G; Stelitano C; Sacchi S;
    Acta Haematol; 2017; 137(1):7-14. PubMed ID: 27820922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationships between chemotherapy, chemotherapy dose intensity and outcomes of follicular lymphoma in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence Molecular Epidemiology Resource.
    Wudhikarn K; Smith BJ; Button AM; Habermann TM; Thompson CA; Rosenstein LJ; Syrbu SI; Weiner GJ; Cerhan JR; Link BK
    Leuk Lymphoma; 2015; 56(8):2365-72. PubMed ID: 25530345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.